OncoTherapy Science, Inc. (4564.T)
- Previous Close
24.00 - Open
23.00 - Bid --
- Ask 24.00 x --
- Day's Range
23.00 - 24.00 - 52 Week Range
15.00 - 64.00 - Volume
1,762,000 - Avg. Volume
2,245,836 - Market Cap (intraday)
6.34B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-4.81 - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company's pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
www.oncotherapy.co.jpRecent News: 4564.T
View MorePerformance Overview: 4564.T
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4564.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4564.T
View MoreValuation Measures
Market Cap
6.62B
Enterprise Value
5.52B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.62
Price/Book (mrq)
6.61
Enterprise Value/Revenue
11.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-108.67%
Return on Assets (ttm)
-49.27%
Return on Equity (ttm)
-150.79%
Revenue (ttm)
750M
Net Income Avi to Common (ttm)
-815M
Diluted EPS (ttm)
-4.81
Balance Sheet and Cash Flow
Total Cash (mrq)
833M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-512.75M